BR112013011480A2 - método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer - Google Patents

método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer

Info

Publication number
BR112013011480A2
BR112013011480A2 BR112013011480A BR112013011480A BR112013011480A2 BR 112013011480 A2 BR112013011480 A2 BR 112013011480A2 BR 112013011480 A BR112013011480 A BR 112013011480A BR 112013011480 A BR112013011480 A BR 112013011480A BR 112013011480 A2 BR112013011480 A2 BR 112013011480A2
Authority
BR
Brazil
Prior art keywords
cancer treatment
pmo1183
kit
enhancing
pharmaceutically acceptable
Prior art date
Application number
BR112013011480A
Other languages
English (en)
Other versions
BR112013011480B1 (pt
BR112013011480A8 (pt
Inventor
Victoria Moneo Ocaña
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Priority to BR122017028568-8A priority Critical patent/BR122017028568B1/pt
Priority to BR122017028570-0A priority patent/BR122017028570B1/pt
Priority to BR122017028566-1A priority patent/BR122017028566B1/pt
Publication of BR112013011480A2 publication Critical patent/BR112013011480A2/pt
Publication of BR112013011480A8 publication Critical patent/BR112013011480A8/pt
Publication of BR112013011480B1 publication Critical patent/BR112013011480B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
BR112013011480-0A 2010-11-12 2011-11-11 Uso de pm01183 ou um sal farmaceuticamente aceitável do mesmo e kit para uso no tratamento de câncer BR112013011480B1 (pt)

Priority Applications (3)

Application Number Priority Date Filing Date Title
BR122017028568-8A BR122017028568B1 (pt) 2010-11-12 2011-11-11 Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um inibidor mitótico e kit
BR122017028570-0A BR122017028570B1 (pt) 2010-11-12 2011-11-11 Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um inibidor da topoisomerase i e/ou ii e kit
BR122017028566-1A BR122017028566B1 (pt) 2010-11-12 2011-11-11 Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um antibiótico anticâncer e kit

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10382300.1 2010-11-12
EP10382300 2010-11-12
PCT/EP2011/069976 WO2012062920A1 (en) 2010-11-12 2011-11-11 Combination therapy with an antitumor alkaloid

Publications (3)

Publication Number Publication Date
BR112013011480A2 true BR112013011480A2 (pt) 2016-08-09
BR112013011480A8 BR112013011480A8 (pt) 2018-01-02
BR112013011480B1 BR112013011480B1 (pt) 2022-03-22

Family

ID=44936282

Family Applications (4)

Application Number Title Priority Date Filing Date
BR122017028566-1A BR122017028566B1 (pt) 2010-11-12 2011-11-11 Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um antibiótico anticâncer e kit
BR122017028568-8A BR122017028568B1 (pt) 2010-11-12 2011-11-11 Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um inibidor mitótico e kit
BR122017028570-0A BR122017028570B1 (pt) 2010-11-12 2011-11-11 Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um inibidor da topoisomerase i e/ou ii e kit
BR112013011480-0A BR112013011480B1 (pt) 2010-11-12 2011-11-11 Uso de pm01183 ou um sal farmaceuticamente aceitável do mesmo e kit para uso no tratamento de câncer

Family Applications Before (3)

Application Number Title Priority Date Filing Date
BR122017028566-1A BR122017028566B1 (pt) 2010-11-12 2011-11-11 Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um antibiótico anticâncer e kit
BR122017028568-8A BR122017028568B1 (pt) 2010-11-12 2011-11-11 Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um inibidor mitótico e kit
BR122017028570-0A BR122017028570B1 (pt) 2010-11-12 2011-11-11 Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um inibidor da topoisomerase i e/ou ii e kit

Country Status (24)

Country Link
US (5) US20130266666A1 (pt)
EP (6) EP2786756B1 (pt)
JP (4) JP6382516B2 (pt)
KR (9) KR102301175B1 (pt)
CN (3) CN105664165A (pt)
AU (4) AU2011328004C1 (pt)
BR (4) BR122017028566B1 (pt)
CA (4) CA2995025C (pt)
CY (4) CY1117466T1 (pt)
DK (4) DK2786753T3 (pt)
ES (4) ES2569180T3 (pt)
HK (5) HK1202419A1 (pt)
HR (4) HRP20160361T1 (pt)
HU (4) HUE042802T2 (pt)
LT (3) LT2786756T (pt)
ME (3) ME03408B (pt)
PL (4) PL2786754T3 (pt)
PT (3) PT2786753T (pt)
RS (4) RS54648B1 (pt)
RU (4) RU2605335C2 (pt)
SI (4) SI2637663T1 (pt)
SM (1) SMT201600112B (pt)
TR (2) TR201904459T4 (pt)
WO (1) WO2012062920A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
DK2786753T3 (en) * 2010-11-12 2019-04-15 Pharma Mar Sa Combination therapy with an antitumor antibiotic
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
KR101588949B1 (ko) * 2014-03-13 2016-01-29 아주대학교산학협력단 플루나리진을 유효성분으로 함유하는 뇌암에 대한 항암 활성 보조제
US11326210B2 (en) * 2015-01-30 2022-05-10 Glax Llc Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
KR20210049403A (ko) * 2019-10-25 2021-05-06 연세대학교 산학협력단 암의 예방 또는 치료용 조성물
CR20220289A (es) * 2019-11-21 2022-10-27 Pharma Mar Sa Métodos de tratamiento del cáncer de pulmón de células pequeñas con formulaciones de lurbinectedina
MA56827B2 (fr) * 2019-11-21 2023-09-27 Pharma Mar Sa Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
WO2021228414A1 (en) * 2020-05-14 2021-11-18 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
CN111298122B (zh) * 2019-12-04 2021-12-21 哈尔滨商业大学 用于治疗小细胞肺癌的药物组合物及其应用
CN113491771A (zh) * 2020-03-18 2021-10-12 苏州大学 小分子化合物在制备glut5摄取转运果糖的抑制剂中的应用
WO2021215952A1 (ru) 2020-04-24 2021-10-28 Общество С Ограниченной Ответственностью "Индженик" Способ получения частиц бактериофагов семейства levivirus
CN112870194B (zh) * 2021-01-06 2022-06-21 广州医科大学附属肿瘤医院 治疗肝癌的组合物及其应用
CN115246846A (zh) * 2021-11-19 2022-10-28 江苏慧聚药业股份有限公司 卢比替定新晶型及其制备
WO2023165603A1 (en) * 2022-03-03 2023-09-07 Zai Lab (Shanghai) Co., Ltd. Dna-pk inhibitor and combination use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
DE3774435D1 (de) 1986-06-09 1991-12-12 Univ Pennsylvania Ekteinascidine 729, 743, 745, 759a, 759b and 770.
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
PT1067933E (pt) 1998-04-06 2007-11-15 Univ Illinois Ecteinascidinas semi-sintéticas
IL139607A0 (en) 1998-05-11 2002-02-10 Pharma Mar Sa Metabolites of ecteinascidin 743
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
US6686470B2 (en) 2000-01-19 2004-02-03 The Trustees Of Columbia University In The City Of New York Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
WO2001077115A1 (en) 2000-04-12 2001-10-18 Pharma Mar, S.A. Antitumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
DE60143911D1 (de) * 2000-11-06 2011-03-03 Pharma Mar Sa Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
SE0102232L (sv) 2001-06-25 2003-02-06 Anoto Ab Förfarande och anordning i ett digitalt kommunikationssystem
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
ATE502635T1 (de) 2002-08-19 2011-04-15 Pfizer Kombinationstherapie gegen hyperproliferative erkrankungen
CN100591691C (zh) 2002-10-18 2010-02-24 马尔药品公司 新型抗肿瘤化合物
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
US7393277B2 (en) * 2003-08-25 2008-07-01 Igt Horseshoe payline system and games using that system
US7622458B2 (en) * 2003-11-13 2009-11-24 Pharma Mar, S.A.U. Combination of ET-743 and a 5-fluorouracil pro-drug for cancer treatment
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
MXPA06013902A (es) * 2004-05-28 2007-01-26 Pfizer Prod Inc Procedimiento para tratar el crecimiento de celulas anormal.
WO2006046079A1 (en) 2004-10-29 2006-05-04 Pharma Mar S.A., Sociedad Unipersonal Formulations comprising ecteinascidin and a disaccharide
DK1827437T3 (da) * 2004-12-15 2012-02-13 Sigma Tau Ind Farmaceuti Kombinationer af terapeutiske midler til cancerbehandling
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
CA2643238C (en) * 2006-02-28 2016-05-03 Pharma Mar, S.A. Improved antitumoral treatments
EP2307003A2 (en) * 2008-05-16 2011-04-13 Pharma Mar S.A. Combination therapy with pm00104 and another antitumor agent
DK2786753T3 (en) * 2010-11-12 2019-04-15 Pharma Mar Sa Combination therapy with an antitumor antibiotic

Also Published As

Publication number Publication date
US20180078550A1 (en) 2018-03-22
SI2786754T1 (sl) 2019-05-31
JP2018100302A (ja) 2018-06-28
HRP20200696T1 (hr) 2020-07-24
HUE042801T2 (hu) 2019-07-29
PL2637663T3 (pl) 2016-08-31
RS54648B1 (en) 2016-08-31
KR102301175B1 (ko) 2021-09-10
HRP20190554T1 (hr) 2019-05-03
HRP20190565T1 (hr) 2019-05-17
US20180078551A1 (en) 2018-03-22
KR20130140071A (ko) 2013-12-23
JP6724055B2 (ja) 2020-07-15
US11590129B2 (en) 2023-02-28
EP2637663A1 (en) 2013-09-18
RU2016144668A (ru) 2018-12-18
RU2018102078A3 (pt) 2021-04-20
RS58609B1 (sr) 2019-05-31
LT2786754T (lt) 2019-04-10
KR20170096065A (ko) 2017-08-23
JP6723815B2 (ja) 2020-07-15
LT2786756T (lt) 2020-05-11
CN105664165A (zh) 2016-06-15
RU2018102080A (ru) 2019-07-19
EP3666275A3 (en) 2020-09-09
TR201903859T4 (tr) 2019-04-22
EP2786756B1 (en) 2020-03-11
BR112013011480B1 (pt) 2022-03-22
CA2995033C (en) 2020-04-28
CA2995025A1 (en) 2012-05-18
CY1121504T1 (el) 2020-05-29
US20180008602A1 (en) 2018-01-11
EP2786756A3 (en) 2014-10-29
CY1117466T1 (el) 2017-04-26
EP2786753B1 (en) 2019-01-09
KR20170057472A (ko) 2017-05-24
DK2637663T3 (en) 2016-04-18
EP3666275A2 (en) 2020-06-17
EP2786755A2 (en) 2014-10-08
AU2017276155B2 (en) 2019-03-07
BR112013011480A8 (pt) 2018-01-02
PT2786756T (pt) 2020-05-07
CA2817420C (en) 2019-09-24
EP2786755A3 (en) 2014-10-29
CN106860870B (zh) 2020-03-31
HK1202419A1 (en) 2015-10-02
HK1202422A1 (en) 2015-10-02
EP2786754B1 (en) 2019-01-09
CY1122904T1 (el) 2021-10-29
AU2017276157A1 (en) 2018-01-04
AU2011328004B2 (en) 2016-07-14
EP2786754A3 (en) 2014-10-29
BR122017028566B1 (pt) 2022-03-03
CN106860870A (zh) 2017-06-20
DK2786753T3 (en) 2019-04-15
CA2995025C (en) 2020-04-28
BR122017028570B1 (pt) 2022-03-03
HK1202421A1 (en) 2015-10-02
CA2995033A1 (en) 2012-05-18
RS58608B1 (sr) 2019-05-31
HK1188572A1 (zh) 2014-05-09
KR20190130078A (ko) 2019-11-20
RU2605335C2 (ru) 2016-12-20
CN103282037A (zh) 2013-09-04
RU2016144668A3 (pt) 2020-03-25
SMT201600112B (it) 2016-07-01
EP2637663B1 (en) 2016-02-24
PL2786753T3 (pl) 2019-09-30
HK1202423A1 (en) 2015-10-02
HUE049389T2 (hu) 2020-09-28
KR101716804B1 (ko) 2017-03-15
JP2013542241A (ja) 2013-11-21
CA2817420A1 (en) 2012-05-18
EP2786756A2 (en) 2014-10-08
KR20170124641A (ko) 2017-11-10
SI2786753T1 (sl) 2019-05-31
ES2569180T3 (es) 2016-05-09
EP2786753A3 (en) 2014-10-29
HRP20160361T1 (hr) 2016-05-06
JP2016138133A (ja) 2016-08-04
ES2790414T3 (es) 2020-10-27
EP2786753A2 (en) 2014-10-08
RU2767664C2 (ru) 2022-03-18
ME03408B (me) 2020-01-20
CA2995018C (en) 2021-04-20
US20230404999A1 (en) 2023-12-21
AU2016200191A1 (en) 2016-02-04
AU2017276157B2 (en) 2019-03-07
RU2018102080A3 (pt) 2021-04-12
AU2011328004C1 (en) 2017-01-19
ME03501B (me) 2020-04-20
JP6724056B2 (ja) 2020-07-15
SI2637663T1 (sl) 2016-05-31
PL2786756T3 (pl) 2020-07-13
DK2786756T3 (en) 2020-04-27
RU2743643C2 (ru) 2021-02-20
EP2786754A2 (en) 2014-10-08
US20130266666A1 (en) 2013-10-10
PL2786754T3 (pl) 2019-07-31
RS60236B1 (sr) 2020-06-30
RU2013126630A (ru) 2014-12-20
JP2018100303A (ja) 2018-06-28
KR20170058454A (ko) 2017-05-26
LT2786753T (lt) 2019-04-10
RU2757373C2 (ru) 2021-10-14
AU2017276155A1 (en) 2018-01-04
ES2719052T3 (es) 2019-07-08
BR122017028568B1 (pt) 2022-03-03
HUE042802T2 (hu) 2019-07-29
AU2011328004A1 (en) 2013-05-30
RU2018102078A (ru) 2019-07-19
KR20210046853A (ko) 2021-04-28
ME02395B (me) 2016-09-20
KR20160088956A (ko) 2016-07-26
CN103282037B (zh) 2017-04-05
PT2786754T (pt) 2019-04-24
DK2786754T3 (en) 2019-04-15
PT2786753T (pt) 2019-04-24
AU2016200191B2 (en) 2018-01-18
WO2012062920A1 (en) 2012-05-18
SI2786756T1 (sl) 2020-07-31
KR20170096224A (ko) 2017-08-23
TR201904459T4 (tr) 2019-05-21
CA2995018A1 (en) 2012-05-18
KR102452022B1 (ko) 2022-10-06
CY1121501T1 (el) 2020-05-29
HUE027516T2 (en) 2016-10-28
ES2719091T3 (es) 2019-07-08
KR102247982B1 (ko) 2021-05-04
JP6382516B2 (ja) 2018-08-29

Similar Documents

Publication Publication Date Title
BR112013011480A2 (pt) método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer
IL276643A (en) Methods to increase the transfer of drugs and the effectiveness of therapeutic agents
BR112015008365A2 (pt) composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
BR112013033940A2 (pt) terapia combinada compreendendo um inibidor de cdk4/6 e um inibidor de pi3k para uso no tratamento de câncer
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
EP3431102A4 (en) THERAPEUTIC MEDICINE INDUCING CELLULAR INJURY FOR USE IN THE TREATMENT OF CANCER
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
EP3686200A3 (en) Bicyclic heterocycle compounds and their uses in therapy
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BR112012008854A2 (pt) combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
BR112015003376A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo , composição farmacêutica e usos de quantidade eficiente
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
WO2011091305A3 (en) Inhibition of axl signaling in anti-metastatic therapy
EP4309671A3 (en) Methods for increasing efficacy of folr1 cancer therapy
EP2740795A4 (en) MEDICAMENT COMPOSITION FOR TREATMENT AND / OR PREVENTION OF CANCER
EP2740798A4 (en) DRUG COMPOSITION FOR CANCER TREATMENT AND / OR PREBUILDING
BR112013011968A2 (pt) composição farmacêutica, métodos de tratamento e usos da mesma
BRPI1009860A2 (pt) composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais
BR112013033078A2 (pt) partícula, composição farmacêutica, conjunto para o tratamento do câncer e método para o tratamento do câncer em um paciente
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
BRPI0908124A2 (pt) Composto, ativador de glucoquinase, composição farmacêutica, uso de um composto ou sal farmacologicamente aceitavél do mesmo, e, métodos de ativação da glucoquinase, e para tratar e/ou prevenir uma doença
BR112014005407A2 (pt) composto, composição farmacêutico, uso do composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de um paciente infectado com hcv
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/11/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.